文献速递泌尿男性生殖肿瘤妇科肿瘤消化系统肿瘤

卡博替尼在晚期实体瘤中的II期随机停药试验

Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.
PubMed 文献 · Eur J Cancer · 2017-10-20

这项多队列II期随机停药试验评估卡博替尼(100 mg每日一次)在九种晚期实体瘤中的抗肿瘤活性,526例患者入组,第12周疾病稳定的患者按1:1随机接受卡博替尼或安慰剂。卵巢癌客观缓解率最高(21.7%),去势抵抗性前列腺癌无进展生存获益最大(中位5.5个月 vs 安慰剂1.4个月;HR 0.14,95%CI 0.04-0.52)。因疗效结果积极和症状改善,随机阶段提前终止并转为开放标签非随机扩展队列。

要点

  • 卵巢癌客观缓解率最高,达21.7%。
  • 去势抵抗性前列腺癌无进展生存获益最大:中位5.5个月 vs 安慰剂1.4个月,HR 0.14(95%CI 0.04-0.52)。
  • 随机阶段因疗效积极提前终止,转为开放标签非随机扩展队列。

核心结论

  • 卡博替尼在部分肿瘤类型中观察到临床抗肿瘤活性,去势抵抗性前列腺癌和卵巢癌在扩展队列中进一步评估。
  • 针对去势抵抗性前列腺癌和肝细胞癌的III期项目已启动。
  • 疗效结局的解读受随机部分提前终止的限制。

研究设计与样本

  • 多队列II期随机停药试验,探索卡博替尼在九种肿瘤类型中的抗肿瘤活性。
  • 卡博替尼100 mg每日一次给药,用于晚期、复发或转移性癌症患者。
  • 第12周疾病稳定的患者按1:1随机接受卡博替尼或安慰剂。
  • 主要终点为第12周客观缓解率和随机阶段的无进展生存。
  • 共入组526例患者。

主要发现

  • 卵巢癌客观缓解率最高,为21.7%。
  • 去势抵抗性前列腺癌无进展生存获益最大:中位5.5个月 vs 安慰剂1.4个月;HR 0.14,95%CI 0.04-0.52。
  • 去势抵抗性前列腺癌、卵巢癌、黑色素瘤、转移性乳腺癌、肝细胞癌和非小细胞肺癌的疾病控制率均>40%。
  • 中位缓解持续时间从转移性乳腺癌的3.3个月到卵巢癌的11.2个月。
  • 因疗效结果积极和症状改善,随机阶段提前终止并转为开放标签非随机扩展队列。

关键数值与推荐

  • 卡博替尼给药剂量为100 mg,每日一次。
  • 随机阶段为第12周疾病稳定患者按1:1随机接受卡博替尼或安慰剂。
  • 主要终点为第12周客观缓解率和随机阶段的无进展生存。

临床怎么用

  • 卡博替尼在去势抵抗性前列腺癌和卵巢癌中观察到抗肿瘤活性,已在扩展队列中进一步评估。
  • 针对去势抵抗性前列腺癌和肝细胞癌的III期项目已启动。
  • 因不良反应而减量的患者占48.7%。
  • 最常见的III-IV级不良事件为乏力(12.4%)、腹泻(10.5%)、高血压(10.5%)和掌跖红斑感觉异常综合征(8.7%)。

局限性

  • 疗效结局的解读受随机部分提前终止的限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cabozantinib is an inhibitor of tyrosine kinases, including MET, vascular endothelial growth factor receptor, AXL and RET. This multi-cohort phase II randomised discontinuation trial explored anticancer activity of cabozantinib in nine tumour types. PATIENTS AND METHODS: Cabozantinib was administered (100 mg, once daily) to patients with advanced, recurrent or metastatic cancers. Those with stable disease at week 12 were randomised 1:1 to cabozantinib or placebo. Primary end-points were objective response rate (ORR) at week 12 and progression-free survival (PFS) in the randomised phase. RESULTS: A total of 526 patients were enrolled. The highest ORR was observed in ovarian cancer (OC) (21.7%); the largest PFS benefit was observed in castration-resistant prostate cancer (CRPC) (median 5.5 versus 1.4 months for placebo; hazard ratio 0.14, 95% confidence interval: 0.04, 0.52). Disease control rates were >40% for CRPC, OC, melanoma, metastatic breast cancer (MBC), hepatocellular carcinoma (HCC) and non-small cell lung cancer. Median duration of response ranged from 3.3 (MBC) to 11.2 months (OC). Encouraging efficacy results and symptomatic improvements prompted early suspension of the randomised stage and conversion to open-label non-randomised expansion cohorts. Dose reductions to manage adverse events (AEs) occurred in 48.7% of patients. The most frequent grade III-IV AEs were fatigue (12.4%), diarrhoea (10.5%), hypertension (10.5%) and palmar-plantar erythrodysesthesia syndrome (8.7%). CONCLUSIONS: Clinical antitumour activity of cabozantinib was observed in a subset of tumour types: CRPC and OC were evaluated further in expansion cohorts. Phase III programs were initiated in CRPC and HCC. Interpretation of efficacy outcomes was limited by early termination of the randomised portion of the trial. TRIAL REGISTRATION NUMBER: NCT00940225.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Schöffski P, Gordon M, Smith DC, et al. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. Eur J Cancer. 2017. PMID: 29059635. doi:10.1016/j.ejca.2017.09.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。